<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1182">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01823653</url>
  </required_header>
  <id_info>
    <org_study_id>12-130-LP-H</org_study_id>
    <nct_id>NCT01823653</nct_id>
  </id_info>
  <brief_title>Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound</brief_title>
  <official_title>A Study to Investigate the Safety and Efficacy of Treatment of Subcutaneous Adipose Tissue in the Thighs Using the Liposonix System (Model 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Solta Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Valeant Pharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of treatment with the
      Liposonix System (Model 2) for the circumferential reduction of subcutaneous adipose tissue
      (SAT) of the thighs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects received a single treatment (Liposonix System) on one randomly assigned thigh. The
      opposite thigh was not treated and served as a control for each subject.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Improvement in Thigh Circumference</measure>
    <time_frame>12 weeks (minus baseline)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical improvement measured by change from baseline thigh circumference after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Showing Clinical Improvement Using the Global Aesthetic Improvement Scale (GAIS) Post Treatment, Assessed by Investigator</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Investigator improvement at 12 weeks using the GAIS Scale, as presented based on percentage of subjects showing improvement. Outcome presented in % of participants that had GAIS scores of either 4 (improved) or 5 (much improved) at 12 weeks post treatment.
*GAIS Scale: 1=Much Worse, 2=Worse, 3=No Improvement, 4=Improved, 5=Much Improved</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction Using 1-5 Likert Scale</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Likert scale ranges from 1=Very Dissatisfied to 4=satisfied, 5=very satisfied. Percentage of participants rated 4 and 5 are reported below</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment</measure>
    <time_frame>1, 4, 8, 12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Discomfort level during treatment using the Visual Analog Scale (VAS) and post-treatment skin reponses or side effects using a 0-3 severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous Adipose Thickness</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ultrasound assisted measurement of adipose tissue thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement Scale (GAIS) Score Post Treatment Assessed by Investigator for Determining Clinical Improvement</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Mean Investigator improvement at 12 weeks using the GAIS Scale.
*GAIS Scale: 1=Much Worse, 2=Worse, 3=No Improvement, 4=Improved, 5=Much Improved</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Treatment of Adipose Tissue in the Thighs</condition>
  <arm_group>
    <arm_group_label>Treated Thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Liposonix System (Model 2)</intervention_name>
    <description>Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound</description>
    <arm_group_label>Treated Thigh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects between 18-60 years of age

          -  Body Mass Index of ≤30 lb/in2

          -  Thickness of adipose tissue is at least 1.0 cm beyond the selected focal depth in the
             area to be treated (≥2.3cm)

          -  Subjects must agree not to alter their regular diet or exercise routines during the
             course of the study

          -  Subjects must be willing and able to comply with all study visit requirements,
             procedures, and assessments

          -  Subject must understand the nature of the study and sign an IRB approved Informed
             Consent

        Exclusion Criteria:

          -  Subjects is pregnant

          -  Subjects diagnosed with a coagulation disorder or receiving anticoagulant therapy

          -  Subject has had prior aesthetic procedures in the area to be treated

          -  Subjects has pacemaker, defibrillator, or other implantable electrical device

          -  Subject has significant circumferential asymmetry between thighs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Van Dyke Laser and Skin</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solta Medical Aesthetic Center</name>
      <address>
        <city>Hayward</city>
        <state>California</state>
        <zip>94545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewell Plastic Surgery Center</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Solish M.D.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <lastchanged_date>December 10, 2014</lastchanged_date>
  <firstreceived_date>March 29, 2013</firstreceived_date>
  <firstreceived_results_date>March 25, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treated Thigh</title>
          <description>Randomly chosen left or right thigh treated with the Liposonix System (Model 2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to Treat Cohort</population>
      <group_list>
        <group group_id="B1">
          <title>Treated Thigh</title>
          <description>Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40.4" spread="8.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="59"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Improvement in Thigh Circumference</title>
        <description>Clinical improvement measured by change from baseline thigh circumference after treatment</description>
        <time_frame>12 weeks (minus baseline)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Thigh</title>
            <description>Randomly assigned left or right thigh that received treatment with Liposonix System (Model 2)</description>
          </group>
          <group group_id="O2">
            <title>Control Thigh</title>
            <description>Each subject's own thigh untreated during study</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Improvement in Thigh Circumference</title>
            <description>Clinical improvement measured by change from baseline thigh circumference after treatment</description>
            <units>centimeter</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-1.22" spread="0.17"/>
                  <measurement group_id="O2" value="-0.59" spread="0.17"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Showing Clinical Improvement Using the Global Aesthetic Improvement Scale (GAIS) Post Treatment, Assessed by Investigator</title>
        <description>Investigator improvement at 12 weeks using the GAIS Scale, as presented based on percentage of subjects showing improvement. Outcome presented in % of participants that had GAIS scores of either 4 (improved) or 5 (much improved) at 12 weeks post treatment.
*GAIS Scale: 1=Much Worse, 2=Worse, 3=No Improvement, 4=Improved, 5=Much Improved</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Thigh</title>
            <description>Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants Showing Clinical Improvement Using the Global Aesthetic Improvement Scale (GAIS) Post Treatment, Assessed by Investigator</title>
            <description>Investigator improvement at 12 weeks using the GAIS Scale, as presented based on percentage of subjects showing improvement. Outcome presented in % of participants that had GAIS scores of either 4 (improved) or 5 (much improved) at 12 weeks post treatment.
*GAIS Scale: 1=Much Worse, 2=Worse, 3=No Improvement, 4=Improved, 5=Much Improved</description>
            <units>Percentage of subjects improved</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="79.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction Using 1-5 Likert Scale</title>
        <description>Likert scale ranges from 1=Very Dissatisfied to 4=satisfied, 5=very satisfied. Percentage of participants rated 4 and 5 are reported below</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Thigh</title>
            <description>Randomly chosen left or right thigh treated with the Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Satisfaction Using 1-5 Likert Scale</title>
            <description>Likert scale ranges from 1=Very Dissatisfied to 4=satisfied, 5=very satisfied. Percentage of participants rated 4 and 5 are reported below</description>
            <units>percentage of subjects satisfied</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Assessment</title>
        <description>Discomfort level during treatment using the Visual Analog Scale (VAS) and post-treatment skin reponses or side effects using a 0-3 severity scale.</description>
        <time_frame>1, 4, 8, 12 weeks</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subcutaneous Adipose Thickness</title>
        <description>Ultrasound assisted measurement of adipose tissue thickness</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Aesthetic Improvement Scale (GAIS) Score Post Treatment Assessed by Investigator for Determining Clinical Improvement</title>
        <description>Mean Investigator improvement at 12 weeks using the GAIS Scale.
*GAIS Scale: 1=Much Worse, 2=Worse, 3=No Improvement, 4=Improved, 5=Much Improved</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Thigh</title>
            <description>Subjects randomly received treatment of either the left or right thigh with the Liposonix System (Model 2)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Global Aesthetic Improvement Scale (GAIS) Score Post Treatment Assessed by Investigator for Determining Clinical Improvement</title>
            <description>Mean Investigator improvement at 12 weeks using the GAIS Scale.
*GAIS Scale: 1=Much Worse, 2=Worse, 3=No Improvement, 4=Improved, 5=Much Improved</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" spread="0.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from day 0 through study exit (12-weeks post treatment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated Thigh</title>
          <description>Randomly chosen left or right thigh treated with the Liposonix System (Model 2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Itchiness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator shall notify Sponsor of the intent to publish or present independent Study Data, and agrees not to publish or publicly present and/or discuss such data, Investigator’s current findings and/or the results of the Study independently without the express written consent of Sponsor, which consent may be withheld. Sponsor reserves the right to require Investigator to remove any/all confidential information from any/all publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Programs</name_or_title>
      <organization>Solta Medical</organization>
      <phone>510-259-5284</phone>
      <email>aloncaric@solta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
